Matrix metalloproteinases in disease and repair processes in the anterior segment

Survey of Ophthalmology

Volumn 47, Issue 3, 2002, Pages 239-256

  Wong, Tina T L ^a,c   Sethi, Charanjit ^a   Daniels, Julie T ^a   Limb, G Astrid ^a   Murphy, Gillian ^b   Khaw, Peng T ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Anterior segment; Aqueous humour; Ciliary body; Conjunctiva; Cornea; Extracellular matrix; Glaucoma; Lens; Matrix metalloproteinase; Trabecular meshwork; Uvea; Wound healing

Indexed keywords

COLLAGEN; COLLAGENASE 3; GELATINASE; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 19; MATRIX METALLOPROTEINASE 20; MATRIX METALLOPROTEINASE 23; MATRIX METALLOPROTEINASE 24; MATRIX METALLOPROTEINASE 25; MATRIX METALLOPROTEINASE 26; MATRIX METALLOPROTEINASE 28; NEUTROPHIL COLLAGENASE; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTERIOR EYE CHAMBER DISEASE; ANTERIOR EYE SEGMENT; ARTICLE; CELL ACTIVATION; CELL SURFACE; COLLAGEN SYNTHESIS; CORNEA; DISEASE COURSE; ENDOTHELIUM; ENZYME ACTIVATION; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME REGULATION; EPITHELIUM; EXTRACELLULAR MATRIX; EYE DISEASE; HUMAN; INFLAMMATION; KERATOCONUS; PATHOGENESIS; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN FAMILY; PTERYGIUM; REGULATORY MECHANISM; SCAR FORMATION; STROMA; SURGICAL TECHNIQUE; TEAR FILM; TRANSCRIPTION REGULATION; VISION; VISUAL DISORDER; WOUND HEALING;

EID: 0036258137     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6257(02)00287-4     Document Type: Review

References (229)

1. Human trabecular meshwork organ culture: Morphology and glycosaminoglycan synthesis
2. Trabecular meshwork glycosaminoglycans in human and cynomolgus monkey eye
3. Histologic characteristics of filtering blebs in glaucomatous eyes
4. Tear fluid gelatinase B activity correlates with IL-1alpha concentration and fluorescein clearance in ocular rosacea
5. Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork
6. Inhibition of collagenolytic activity and metastasis of tumour cells by a recombinant human tissue inhibitor of metalloproteinases
7. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3
8. MMPs and proteinase inhibitors in the human aqueous humor
9. Prostaglandin F2 alpha receptors in the human trabecular meshwork
10. The matrix metalloproteinase-14 (MMP-14) gene is structurally distinct from other MMP genes and is co-expressed with the TIMP-2 gene during mouse embryogenesis
11. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family
12. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis
13. Matrix metalloproteinases are expressed during wound healing after excimer laser keratectomy
14. Matrix metalloproteinase family
15. Inhibition of pseudomonal ulceration in rabbit corneas by a synthetic matrix metalloproteinase inhibitor
16. Gelatinase concentration in tears of corneal-grafted patients
17. Urokinase-type plasminogen activator in human aqueous humor
18. Long-term sun exposure alters the collagen of the papillary dermis. Comparison of sun-protected and photoaged skin by northern analysis, immunohistochemical staining, and confocal laser scanning microscopy
19. Enhanced elastin and fibrillin gene expression in chronically photodamaged skin
20. Differential expression of the versican and decorin genes in photoaged and sun-protected skin. Comparison by immunohistochemical and northern analyses
21. Uveoscleral drainage of aqueous humor: Physiology and pharmacology
22. The drainage of aqueous humour
23. From tadpole collagenase to a family of matrix metalloproteinases
24. Insights into MMP-TIMP interactions
25. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: An absolute requirement for transcription factor NF-kappa B
26. Identification of a stimulator of steroid hormone synthesis isolated from testis
27. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture
28. Prolonged activation of jun and collagenase genes by tumour necrosis factor-alpha
29. Tissue inhibitors of metalloproteinases: Evolution, structure and function
30. Keratoconus corneas: Increased gelatinolytic activity appears after modification of inhibitors
31. Tissue inhibitor of metalloproteinases-1 is decreased and activated gelatinases are increased in chronic wounds
32. Human trabecular meshwork phagocytosis. Observations in an organ culture system
33. Acute inflammatory cells and collagenase in tears of human melting corneas
34. Membrane-type-2 matrix metalloproteinase can initiate the processing of progelatinase A and is regulated by the tissue inhibitors of metalloproteinases
35. The AP-1 site is required for basal expression but is not necessary for TPA-response of the human stromelysin gene
36. Matrix metalloproteinases and TIMPs: Properties and implications for the rheumatic diseases
37. Matrix metalloproteinase inhibitors and the prevention of connective tissue breakdown
38. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: An overview
39. Effects of synthetic inhibitor of metalloproteinase and cyclosporin A on corneal haze after excimer laser photorefractive keratectomy in rabbits
40. Re-epithelialization of normal human excisional wounds is associated with a switch from alpha v beta 5 to alpha v beta 6 integrins
41. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen
42. Human dermal microvascular endothelial cells produce matrix metalloproteinases in response to angiogenic factors and migration
43. Pterygium as an early indicator of ultraviolet insolation: A hypothesis
44. Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells
45. Fos and Jun: The AP-1 connection
46. Alpha-smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing
47. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor
48. Inhibition of invasion and metastasis in cell transfected with an inhibitor of metalloproteinases
49. Wound healing after filtering surgery in owl monkeys
50. Expression of MMPs and TIMPs in human pterygia and cultured pterygium epithelial cells
51. Increased matrix metalloproteinases in the aqueous humor of patients and experimental animals with uveitis
52. Matrix metalloproteinases and cardiovascular disease
53. Involvement of AP1 and PEA3 binding sites in the regulation of murine tissue inhibitor of metalloproteinases-1 (TIMP-1) transcription
54. Vanadate and the absence of myofibroblasts in wound contraction
55. Proteolytic mechanisms in corneal ulceration and repair
56. Expression of collagenolytic/gelatinolytic metalloproteinases by normal cornea
57. Role of matrix metalloproteinses in failure to re-epithelialize after corneal injury
58. Collagenolytic/gelatinolytic metalloproteinases in normal and keratoconus corneas
59. Molecular basis of sun-induced premature skin ageing and retinoid antagonism
60. Localization of matrix metalloproteinases-1, -2, and -9 and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases
61. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction
62. Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey
63. Wound repair in the context of extracellular matrix
64. Radial keratotomy. II. Role of the myofibroblast in corneal wound contraction
65. Matrix metalloproteinases in epithelia from human recurrent corneal erosion
66. Matrix metalloproteinase-1 localization in the normal human uveoscleral outflow pathway
67. Matrix metalloproteinases in sterile corneal melts
68. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5
69. Transforming growth factor-beta and interleukin-1 modulate metalloproteinase expression by corneal stromal cells
70. Matrix metalloproteinases in immunity
71. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions
72. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4
73. Phagocytosis of latex microspheres by bovine meshwork cells in culture
74. Specific degradation of the collagen molecule by tadpole collagenolytic enzyme
75. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1
76. The effects of single mitomycin C application on the expression of matrix metalloproteinases in the sclera and aqueous of albino rabbits
77. Proteoglycan changes during restoration of transparency in corneal scars
78. Cell growth-promoting activity of tissue inhibitor of metalloproteinase-2 (TIMP-2)
79. Growth promoting activity of tissue inhibitor of metalloproteinase-1 (TIMP-1) for a wide range of cells
80. Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation
81. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins
82. Clinicopathological correlation in eyes with failed fistulizing surgery
83. Bronchial subepithelial fibrosis and expression of matrix metalloproteinase-9 in asthmatic airway inflammation
84. Matrix metalloproteinases and their inhibitors in aqueous humor
85. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and glycosaminoglycans in synovial fluid from patients with rheumatoid arthritis
86. Preferential inactivation of tissue inhibitor of metalloproteinases-1 that is bound to the precursor of matrix metalloproteinase 9 (progelatinase B) by human neutrophil elastase
87. Cellular proliferation after experimental glaucoma filtration surgery
88. Hypotony maculopathy following trabeculectomy with mitomycin C
89. Transforming growth factor-beta in human aqueous humor
90. Collagen and collagenase: Pregnancy and parturition
91. Expression of alpha-smooth muscle (alpha-SM) actin during corneal stromal wound healing
92. Matrix metalloproteinases
93. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase
94. Matrix metalloproteinases and their inhibitors in tumour growth and invasion
95. Basement membrane collagen: Degradation by migrating endothelial cells
96. Pterygium in welders
97. Mitomycin-C versus 5-fluorouracil in high-risk glaucoma filtration surgery: Extended follow-up
98. Immunolocalization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human subconjunctival tissues
99. Localization of TIMP-1, TIMP-2, TIMP-3, gelatinase A and gelatinase B in pathological human corneas
100. Altered gelatinolytic activity by keratoconus corneal cells
101. In vivo characterization of host and bacterial protease expression during Pseudomonas aeruginosa corneal infections in naive and immunized mice
102. In vivo bacterial protease production during Pseudomonas aeruginosa corneal infection
103. Growth factors regulate transin gene expression by c-fos-dependent and c-fos-independent pathways
104. Isolation and characterization of gelatinase granules from human neutrophils
105. Structural biochemistry and activation of matrix metalloproteases
106. Aqueous outflow pathway glycosaminoglycans
107. UV irradiation induces the expression of gelatinases in human skin in vivo
108. Matrix metalloproteinase-19 in capillary endothelial cells: Expression in acutely, but not in chronically, inflamed synovium
109. The matrix metalloproteinase RASI-1 is expressed in synovial blood vessels of a rheumatoid arthritis patient
110. A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy
111. Matrix metalloproteinase (MMP)-9 type IV collagenase/gelatinase implicated in the pathogenesis of Sjogrens syndrome
112. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis
113. Tissue inhibitor of metalloproteinases-1 (TIMP-1) RNA is expressed at elevated levels in malignant non-Hodgkin's lymphomas
114. An in-vivo technique for monitoring keratocyte migration following lamellar keratoplasty
115. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization
116. 5-Fluorouracil and mitomycin-C in pseudophakic patients
117. Control of tumor growth in animals by infusion of an angiogenesis inhibitor
118. Single intraoperative applications of 5-fluorouracil during filtration surgery: Early results
119. Localization of type IV collagen, laminin, heparan sulfate proteoglycan, and fibronectin to the basal lamina of basement membranes
120. Overexpression of collagenase (MMP-1) and stromelysin (MMP-3) by pterygium head fibroblasts
121. Overexpression of MMP-1 and MMP-3 by cultured conjunctivochalasis fibroblasts
122. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells
123. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: Implications for uveoscleral outflow
124. Conjunctivochalasis: A cause of tearing and its management
125. Matrix metalloproteinases (MMPs) and their physiological inhibitors (TIMPs) are differentially expressed during excisional skin wound repair
126. Immunoconfocal localization of gelatinase B expressed by migrating intrastromal epithelial cells after deep annular excimer keratectomy
127. Lens cell populations studied in human donor capsular bags with implanted intraocular lenses
128. Matrix metalloproteinases: Structures, evolution, and diversification
129. Differential roles for two gelatinolytic enzymes of the matrix metalloproteinase family in the remodelling cornea
130. Localisation of prostaglandin F2 alpha and E2 binding sites in the human eye
131. Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts
132. The extracellular matrix produced by bovine corneal endothelial cells contains progelatinase A
133. Effects of collagenase-cleavage of type I collagen on alpha2beta1 integrin-mediated cell adhesion
134. TGF-beta plays a key role in morphogenesis of the pancreatic islets of Langerhans by controlling the activity of the matrix metalloproteinase MMP-2
135. Pterygium and ultraviolet radiation: A positive correlation
136. The regulation of neovascularization of matrix metalloproteinases and their inhibitors
137. Temporal study of the activity of matrix metalloproteinases and their endogenous inhibitors during wound healing
138. Tissue inhibitors of matrix metalloendopeptidases
139. Regulation of matrix metalloproteinase activity
140. Cell surface activation of progelatinase A (proMMP-2) and cell migration
141. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens
142. Extracellular matrix and growth factors in corneal wound healing
143. MMP-8 is the predominant collagenase in healing wounds and nonhealing ulcers
144. Dynamics of the matrix metalloproteinases MMP-1 and MMP-8 in acute open human dermal wounds
145. Wound Healing: Laboratory investigation and modulating agents
146. Inhibition of matrix metalloproteinases inhibits anterior segment fibroblast mediated collagen contraction
147. Localization of the prostaglandin F2 alpha receptor messenger RNA and protein in the cynomologus monkey eye
148. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9
149. The precursor of a metalloendopeptidase from human rheumatoid synovial fibroblasts. Purification and mechanisms of activation by endopeptidases and 4-aminophenylmercuric acetate
150. The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy
151. Late endophthalmitis - Filtering surgery time bomb?
152. Laser trabeculoplasty induces stromelysin expression by trabecular juxtacanalicular cells
153. Early changes in matrix metalloproteinases and inhibitors after in vitro laser treatment to the trabecular meshwork
154. Recombinant tissue inhibitor of metalloproteinases type 1 suppresses alkali-burn-induced corneal ulceration in rabbits
155. Furin-dependent intracellular activation of the human stromelysin-3 zymogen
156. Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution
157. Ultraviolet A irradiation stimulates collagenase production in cultured human fibroblasts
158. Corneal ulceration and perforation associated with Sjogrens syndrome
159. Role of matrix metalloproteinases and their inhibition in cutaneous wound healing and allergic contact hypersensitivity
160. Bulbar conjunctivo-chalasis
161. Preovulatory changes in ovarian expression of collagenases and tissue metalloproteinase inhibitor messenger ribonucleic acid: Role of eicosanoids
162. Collagenases and tissue inhibitors of metalloproteinases: A functional balance in tissue degradation
163. The phagocytic activity of the trabecularmeshwork endothelium. An electron-microscopic study of the vervet (Cercopithecus aethiops)
164. Accumulation of matrilysin (MMP-7) and macrophage metalloelastase (MMP- 12) in actinic damage
165. Distinct populations of basal keratinocytes express stromelysin-1 and stromelysin-2 in chronic wounds
166. Regulation of the levels of human trabecular matrix metalloproteinases and inhibitor by interleukin-1 and dexamethasone
167. Activation of human progelatinase A by collagenase and matrilysin: Activation of procollagenase by matrilysin
168. Complex role of matrix metalloproteinases in angiogenesis
169. Characterization of structural determinants and molecular mechanisms involved in pro-stromelysin-3 activation by 4-aminophenylmercuric acetate and furin-type convertases
170. Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2
171. The migration of purified osteoclasts through collagen is inhibited by matrix metalloproteinase inhibitors
172. Pterygium: Prevalence, demography and risk factors
173. Lens epithelial cell proliferation, migration, and metaplasia following capsulorhexis
174. Synthesis and composition of glycosaminoglycans by cultured human trabecular meshwork cells
175. UVA irradiation induces collagenase in human dermal fibroblasts in vitro and in vivo
176. Requirement for fos gene expression in the transcriptional activation of collagenase by other oncogenes and phorbol esters
177. Treatment of alkali-injured rabbit corneas with a synthetic inhibitor of matrix metalloproteinases
178. A matrix metalloproteinase inhibitor which prevents fibroblast-mediated collagen lattice contraction
179. Matrix metalloproteinase MMP-19 (RASI-1) is expressed on the surface of activated peripheral blood mononuclear cells and is detected as an autoantigen in rheumatoid arthritis
180. Membrane-type matrix metalloproteinases
181. Complications of myopic photorefractive keratectomy with the excimer laser
182. Myopic photorefractive keratectomy with the excimer laser. One-year follow-up
183. Matrix metalloproteinase biology applied to vitreoretinal disorders
184. Matrix metalloproteinase degradation of extracellular matrix: Biological consequences
185. Kinetics of phagocytosis in trabecular meshwork cells. Flow cytometry and morphometry
186. Tissue plasminogen activator in cultured human trabecular meshwork cells. Predominance of enzyme over plasminogen activator inhibitor
187. Wound healing in glaucoma filtering surgery
188. Co-agenase in corneal ulcerations
189. Membrane type-1 matrix metalloproteinase in human ocular tissues
190. Over-expression of a gelatinase A activity in keratoconus
191. Tear film MMP accumulation and corneal disease
192. Regulation of MMP-9 activity in human tear fluid and corneal epithelial culture supernatant
193. Regulation of collagenase, stromelysin, and urokinase-type plasminogen activator in primary pterygium body fibroblasts by inflammatory cytokines
194. Doyne Lecture. Glaucoma: Facts and fancies
195. Scientific basis of a matrix metalloproteinase-8 specific chair-side test for monitoring periodontal and peri-implant health and disease
196. Hypotonous maculopathy after trabeculectomy with subconjunctival 5-fluorouracil
197. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family
198. Prostaglandins as ocular hypotensive agents; Development of an analogue for glaucoma treatment
199. Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19. Evidence for a role as a potent basement membrane degrading enzyme
200. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease
201. Identification of the second membrane-type matrix metalloproteinase (MT- MMP-2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family
202. Induction of matrix metalloproteinases 2 and 9 following stress to the lens
203. Global data on blindness
204. Prostaglandin A2 increases uveoscleral outflow and trabecular outflow facility in the cat
205. Aqueous humor dynamics in the aging human eye
206. Components of the nuclear signaling cascade that regulate collagenase gene expression in response to integrin-derived signals
207. Tissue plasminogen activator in human aqueous humor and its possible therapeutic significance
208. Proteolytic degradation of extracellular matrix in tumor invasion
209. Differential expression of tissue inhibitors of metalloproteinases (TIMP-1, -2, -3, and -4) in normal and aberrant wound healing
210. Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds
211. A latent collagenase in human aqueous humor
212. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis
213. Chemical injuries of the eye: Current concepts in pathophysiology and therapy
214. The role of cytokines in the pathogenesis of inflammatory eye disease
215. Aqueous humour cytokine profile in patients with chronic uveitis
216. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells
217. Regulation of matrix metalloproteinase expression in tumor invasion
218. Two activator protein-1 elements in the matrix metalloproteinase-1 promoter have different effects on transcription and bind Jun D, c-Fos, and Fra-2
219. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3
220. UVA-induced autocrine stimulation of fibroblast-derived collagenase/MMP- 1 by interrelated loops of interleukin-1 and interleukin-6
221. Matrix metalloproteinases and their inhibitors in connective tissue remodeling
222. Matrix metalloproteinase inhibition. From the Jurassic to the third millennium
223. A hypothesis on the pathogenesis of pterygiums
224. Human lens epithelial cell proliferation in a protein-free medium
225. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9
226. Excessive synthesis of matrix metalloproteinases in exocrine tissues of NOD mouse models for Sjogrens syndrome
227. Differential expression of MT1-MMP (MMP-14) and collagenase III (MMP- 13) genes in normal and wounded rat corneas
228. Lysosomal enzyme activities in cultured trabecular-meshwork cells
229. Expression of degradative enzymes and protease inhibitors in corneas with keratoconus